Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in MNPR held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 1.3M | $121.7M | — | 19.587% | 0.05% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 667K | $61.8M | 0.0% | 9.960% | 0.54% |
| 3 | BlackRock, Inc. | 349K | $32.3M | +10.2% | 5.207% | 0.00% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 324K | $30.0M | 0.0% | 4.833% | 0.31% |
| 5 | Saturn V Capital Management LP | 312K | $28.9M | -9.7% | 4.657% | 4.14% |
| 6 | Siren, L.L.C. | 270K | $25.0M | 0.0% | 4.032% | 0.51% |
| 7 | ADAR1 Capital Management, LLC | 218K | $20.1M | -17.7% | 3.248% | 0.92% |
| 8 | Polar Capital Holdings Plc | 214K | $19.9M | -5.3% | 3.202% | 0.05% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 210K | $19.4M | -4.0% | 3.131% | 0.00% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 209K | $19.4M | -32.3% | 3.123% | 0.03% |
| 11 | TCG Crossover Management, LLC | 203K | $18.8M | +53.9% | 3.035% | 0.45% |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 158K | $14.7M | -9.1% | 2.365% | 0.00% |
| 13 | ORBIMED ADVISORS LLC | 157K | $14.6M | — | 2.350% | 0.27% |
| 14 | Candriam S.C.A. | 143K | $13.3M | — | 2.140% | 0.06% |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 135K | $12.5M | -1.4% | 2.008% | 0.02% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 113K | $10.4M | +12.7% | 1.681% | 0.00% |
| 17 | Alyeska Investment Group, L.P. | 100K | $9.3M | 0.0% | 1.493% | 0.02% |
| 18 | STATE STREET CORP | 93K | $8.6M | +4.8% | 1.382% | 0.00% |
| 19 | Vivo Capital, LLC | 91K | $8.4M | 0.0% | 1.351% | 0.77% |
| 20 | DRIEHAUS CAPITAL MANAGEMENT LLC | 84K | $7.8M | +153.5% | 1.255% | 0.05% |
| 21 | Bank of New York Mellon Corp | 77K | $7.1M | -2.1% | 1.149% | 0.00% |
| 22 | Vestal Point Capital, LP | 76K | $7.0M | +15.8% | 1.130% | 0.16% |
| 23 | Longaeva Partners L.P. | 56K | $5.2M | — | 0.834% | 0.11% |
| 24 | Neuberger Berman Group LLC | 55K | $5.1M | +30.1% | 0.824% | 0.00% |
| 25 | MILLENNIUM MANAGEMENT LLC | 50K | $4.7M | -5.0% | 0.751% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in MNPR — a direct measure of their conviction.
Filings activity in MNPR during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 95 | +16% | 92.88% | 0.39 pp | $575M | +70% |
| Q1 2026 | 82 | +12% | 93.27% | +10.61 pp | $339M | 5.4% |
| Q4 2025 | 73 | +33% | 82.66% | +17.46 pp | $358M | +1.1% |
| Q3 2025 | 55 | +25% | 65.20% | +13.26 pp | $354M | +214% |
| Q2 2025 | 44 | +22% | 51.94% | +4.65 pp | $113M | +3.5% |
| Q1 2025 | 36 | +89% | 47.29% | +4.96 pp | $109M | +91% |
| Q4 2024 | 19 | +171% | 42.33% | +41.88 pp | $57M | +53861% |
| Q3 2024 | 7 | — | 0.45% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.
| Ticker | Company | Market Cap | Inst. Ownership | Holders | Net Buyers − Sellers |
|---|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $39M | 23.9% | 42 | -29 |
Quick answers to the most common questions about buying MNPR stock.
Based on Q2 2026 13F filings, institutional ownership of Monopar Therapeutics Inc. stands at 92.9%, held across 95 reporting institutions.
Jupiter Topco LLC is the largest reported institutional holder of MNPR, with approximately 1,312,129 shares worth $0.12B as of Q2 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of MNPR, including MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for MNPR is 49 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
27 institutions opened new positions in MNPR during Q2 2026, while 14 fully exited. 58 added to existing positions and 8 trimmed.
MNPR institutional ownership fell by 0.39 percentage points quarter-over-quarter, with a net change of +13 holders.
The top 10 institutions account for 65.8% of all reported 13F value in MNPR, and the top 25 account for 91.4%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.